Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: March

. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat...

Right Turn: StemCellTalks in Tweets

. Last month (March 13), StemCellTalks held a symposium on diabetes and stem cell tourism to educate Toronto high school students about the field. (These events happen across Canada.) The morning session began with Dr. Elia Piccinini (University of Toronto) giving an...

Grow your brains: Neural stem cells in 1 minute.

> Many of us only become acutely aware of our brain when it’s not working quite right. Like, say, if we have a migraine, or are diagnosed with a mental illness. Or we fall on the ice and give ourself a concussion that affects our vision, motor skills and...

Update from the clinic: January

. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug...

Bad luck, bad science, or bad reporting?

. If you’ve been on the Internet at all in 2015, you’ve probably stumbled across headlines like “Two-thirds of cancers are due to ‘back luck,’ study finds” (CBSNews), “Most cancers are caused by bad luck not genes or lifestyle say scientists” (The Telegraph), “Cause...